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a  b  s  t  r  a  c  t
Aim:  To  investigate  the  predictive  value  of  convenience  of rectum  dosimetry  with  Quantitative  Analysis
of  Normal  Tissue  Effects  in  the Clinic  (QUANTEC)  dose  limits,  maximum  rectum  dose  (Dmax),  total  rectal
volume (TVrectum),  rectal  volume  included  in  PTV  (VrectumPTV)  on Grade  2–3  acute  rectal  toxicity  for
utilization  in  clinical  practice.
Background:  Numerous  previous  data have  reported  frequent  acute  proctitis  after  external-beam  RT  of
prostate cancer.  Predicting  toxicity  limited  with  dose  information  is inadequate  in  clinical  practice  due
to  comorbidities  and  medications  used.
Materials  and Method:  Sixty-four  non-metastatic  prostate  cancer  patients  treated  with  IMRT  were
enrolled.  Patients  were  treated  to a  total  dose  of  70–76  Gy.  Rectal  dose  volume  histograms  (DVH)  of
all  patients  were  evaluated  retrospectively,  and  a QUANTEC  Score  between  0 and  5 was  calculated  for
each patient.  The  correlation  between  the rectal  DVH  data,  QUANTEC  score,  TVrectum,  VrectumPTV,
rectum  Dmax  and Grade  2–3  rectal  toxicity  was investigated.
Results: In  the  whole  group  grade  1, 2 and  3  acute  rectal  toxicities  were  25%,  18.8%  and  3.1%,  respec-
tively.  In  the  DVH  data,  rectum  doses  of  all  patients  were  under  RTOG dose  limits.  Statistically  significant
correlation  was  found  between  grade  2–3  rectal  toxicity  and  TVrectum  (p  = 0,043);  however.  It was  not
correlated  with  QUANTEC  score,  VrectumPTV  and  Dmax.
Conclusion:  Our  results  were  not  able  to  show  any  significant  correlation  between  increasing  convenience
with  QUANTEC  limits  and lower  rectal  toxicity.  Conclusively,  new  dosimetric  definitions  are  warranted
to  predict  acute  rectal  toxicity  more  accurately  in prostate  cancer  patients  during  IMRT  treatment.
© 2019 Greater  Poland  Cancer  Centre.  Published  by Elsevier  B.V. All  rights  reserved.. Background
Numerous previous data have reported acute proctitis fre-
uency after external-beam RT of prostate cancer with conven-
ional fractionation, hypofractionation or SBRT between 5–20%.1–3
he most common method of predicting the normal tissue com-
lication probability after RT is the Lyman-Kutcher-Burman (LKB)
odel,4 a method based on dose-volume histograms. Burman et al.
ere the first to compute the model parameters for late rectal
leeding.5 QUANTEC recently recommended new values to apply
KB model for the same endpoint.6–8 In the last decade many
tudies have been published about NTCP models for various end
oints, such as late rectal bleeding, moderate/mild toxicity as high
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toxicity limited with dose information is a restrictive aspect of tra-
ditional NTCP which is confirmed by plenty of consequent studies
identifying many individual factors, such as drugs used (anti-
hypertensives and/or anti-coagulants), smoking history, previous
abdominal surgery, comorbidities (hypertension, cardiovascular
history, diabetes mellitus), presence of acute gastro-intestinal tox-
icity with rectal injury.10,13–17
The definition of toxicity after radiotherapy is also a complicated
issue. Several different scales have been introduced and validated
in an attempt to ensure an accurately reported toxicity with a com-
mon  language.18–20
Radiation-induced proctopathy can arise with rectal pain,
cramps, incontinence, diarrhea, mucus, rectal bleeding, and
increased frequency of bowel movements. These symptoms are
classified according to the EORTC/RTOG grading system for gas-
trointestinal side effects.20 However, rectal mucosal damage is not
erved.
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Table  1
RTOG Dose suggestions in protocol 415.
Dose/fx Volume Dose
aD50 1.8 Gy 50% <60 Gy
bD35 1.8 Gy 35% <65 Gy
cD25 1.8 Gy 25% <70 Gy
dD15 1.8 Gy 15% <75 Gy















































QUANTEC Dose suggestions (predicted <10% Gr 3 rectal toxicity).






a Volume of rectum that was  exposed to 50 Gy.
b Volume of rectum that was  exposed to 60 Gy.
c Volume of rectum that was  exposed to 65 Gy.b Dose that 35% of rectum volume exposed.
c Dose that 25% of rectum volume exposed.
d Dose that 15% of rectum volume exposed.
irectly correlated with clinical symptoms; therefore. endoscopy
s recommended for accurate estimation of the rectal mucosal sta-
us and radiation-induced changes. Type and severity of mucosal
amage is found to be dependent on the total dose and irradiated
olume.21,22
. Aim
In this study, we retrospectively evaluated the dosimetric data
nd cute rectal toxicity profile of prostate carcinoma patients for
hom we performed IMRT planning by taking into considera-
ion RTOG tolerance dose suggestions for critical organs. QUANTEC
core between 0 and 5 was calculated for each patient according
o the number of parameters that matched the tolerance doses
efined in QUANTEC. The predictive value of QUANTEC Score,
max, TVrectum, VrectumPTV on Grade 2–3 acute rectal toxicity
as investigated.
. Methods and materials
We  retrospectively evaluated the dose – volume data of 64
atients who received definitive IMRT for prostate cancer between
anuary 2015 and February 2018. Patients with biopsy proven
rostate cancer who received neoadjuvant and concurrent hor-
onal therapy were included. The DVH data for 64 patients were
eevaluated in terms of rectal toxicity suggestions from QUANTEC.
he acute toxicity reports were recorded weekly during the treat-
ent, and monthly for the first 3 months after the treatment. All
ectal complications were graded using the criteria from RTOG.
.1. RT techniques
All patients underwent simulation and treatment in a supine
osition with a full bladder. Vacuum-lock bags were used for immo-
ilization. CT images using a 2.5-mm slice thickness for planning
ere acquired for IMRT on a CT scanner (Excel Select, General Elec-
ric Medical Systems). The clinical target volume 1 (CTV 1) for
he initial 46 Gy included the prostate and seminal vesicles and
he pelvic lymph nodes (internal iliac, external iliac, obturatory).
onsequently, the seminal vesicles and prostate were contoured
s CTV 2 treated to 70 Gy. Afterwards, the prostate in interme-
iate risk or the prostate + proximal seminal vesicles in high risk
atients were treated to 76 Gy as CTV 3. PTV was  0.5 cm around
he CTV in the anterior, superior and inferior directions and 0.3 cm
n the posterior direction. The details of RT have been previously
escribed (16). In brief, patients were initially treated to 46 Gy at
 Gy/ fraction to the isocenter using 6-MV photons with seven-field
ntensity modulated radiotherapy. After the initial 46 Gy, a five-
eld IMRT approach was used to boost the total isocenter dose to
6 Gy. All patients were treated at 2 Gy/fraction using 6-MV pho-
ons prescribed to the isocenter. Daily position reproducibility was
rovided via skin marks and daily electronic portal films. RTOG
uggestions were considered in terms of rectum and bladder dose
imitations were (Table 1).d Volume of rectum that was  exposed to 70 Gy.
e Volume of rectum that was  exposed to 75 Gy.
3.2. Dosimetric evaluation
DVH data of all patients were investigated in terms of accor-
dance with QUANTEC suggestions (Table 2). The convenience of
rectum dose parameters with QUANTEC criteria was  scored as 0–5
(0: none of the parameters were within the QUANTEC limits -5:
all parameters were within the QUANTEC limits) for each patient.
Acute rectal toxicity is reported weekly during the treatment and
monthly utill 3 months after the treatment using RTOG toxicity
grading system (Table 3).23
3.3. Statistical analysis
The V50, V60, V65, V70, V75 (volume exposed to dose higher
than indicated), TVrectum, VRectumPTV, Dmax values for the 2
defined groups (Gr 0–1 and 2–3 acute rectal toxicity) were com-
pared via independent samples t test and Mann–Whitney U test
in parametric and nonparametric data, respectively. The correla-
tion between V50, V60, V65, V70, V75 and Grade 2–3 acute rectal
toxicity and the correlation of Grade 2–3 acute rectal toxicity with
QUANTEC score, TVrectum, VRectumPTV and rectum Dmax were also
analyzed via Spearman’s correlation.
4. Results
Acute rectal toxicity distribution among patients according to
grade is shown in Table 4. Of the 64 patients studied, 14 had Grade
2 or higher acute rectal complications. No patient developed Grade
4 complications (Table 4). The median time to developing Grade 2
or higher complications was 3 weeks.
In the whole group, grade 1, 2 and 3 acute rectal toxicities were
25%, 18.8% and 3.1% respectively. DVH data in terms of rectum doses
of all patients were convenient with RTOG rectum tolerance dose
suggestions determined by D50, D35, D25, and D15. QUANTEC score
was 0, 1, 2, 3, 4 and 5 in 3, 5, 6, 3, 13, 34 patients, respectively.
Median Dmax, TVrectum and VrectumPTV values for the whole group
were 78 Gy (72,25–80,62 Gy); 63,83cc(23,18–139,57cc) and 18,29%
(5,39–59,01%), respectively. Mean V50, V60, V65, V70 and V75
values were calculated as 45,45% (±9,56), 29,33% (±7,92), 22,01%
(±7,22), 14,5% (±6,64) and 6,5% (±4,73), respectively. No statis-
tically significant difference was  found between mean V50, V60,
V65, V70 and V75 values of the 2 groups (p = 0,354–0,0,712). Dmax
and VrectumPTV were also not significantly different between the
2 groups (p = 0,175 ve p = 0,0845). However, the TVrectum differ-
ence was statistically significant (p = 0,044). Gr 2–3 acute rectal
toxicity was  not correlated with V50, V60, V65, V70 and V75 vol-
umes (p = 0,18–0,75). Spearman’s correlation analysis for QUANTEC
score, Dmax, TVrectum, VrectumPTV and Gr 2–3 acute rectal toxic-
ity was  found statistically significant only for TVrectum (p < 0,05)
Correlation coefficients are shown in Table 5.
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Table  3
RTOG acute rectal toxicity grading system.
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
No changes Increased frequency,





















Frequency of acute rectal toxicity.
Toxicity Frequency Percent
GR 0 34 53,1
GR  1 16 25
GR  2 12 18,8
GR  3 2 3,1
Table 5
Results of Spearman’s rank correlation coefficients of duration of Grade 2–3 rectal
toxicity.
Correlation coefficient p
QUANTEC score (0–5) 0.061 0.611


































Rectum-PTV : Percent of rectum volume inside PTV, Dmax: Maximum rectum dose.
a Statistically significant p value.
. Discussion
Radiotherapeutic treatment modalities for localized prostate
ancer (PCa) include different types of external-beam radia-
ion therapy (EBRT) or brachytherapy administrations, with or
ithout androgen deprivation.24 Treatment modality preference
epends on numerous factors such as patient age, comorbidi-
ies, tumor stage, grade, intent and institutional standards and
vailabilities.25–27 Recent improvement of RT planning and deliv-
ry and application ensured a reduction in both acute and late
ide-effects.12–14,28–31 These technical developments provided tar-
et dose escalation resulting in better cancer control rates and
ewer or similar side-effects.32–35 Intensity-modulated radiation
herapy (IMRT) ensures more conformal treatment while mitigat-
ng the harmful exposure to the rectum in terms of both acute and
ate toxicity.36–39 In addition, real-time tracking of the target as in
mage-guided tomotherapy or volumetric-modulated arc therapy
llows more accurate dose delivery.40,41 Despite these improve-
ents, acute and late rectal toxicity still remains as to be the main
ose-limiting issue.42,43
.1. Post RT rectal injury: clinic and mucosal detection
Improved local tumor control with higher doses is demon-
trated by many randomized trials; however, dose escalation
auses acute and late side effects.30,35,44 Rectal complications are
ost frequently considered dose limiting in prostate radiotherapy.
n order to report acute and late toxicity, usually Radiation Therapy
ncology Group (RTOG) toxicity scale is used.45 We  also scored
cute rectal toxicity according to RTOG scale. However, some
odifications have been proposed to the criteria based on patientharacteristics such as advanced age; rectal volume; a history
f prior abdominal surgery; the concomitant use of androgen
eprivation; and preexisting diabetes mellitus, hemorrhoids,
r inflammatory bowel disease (IBD).23,30,46–49 In addition, adistention tenesmus requiring tube
decompression or
diversion
diagnosis of acute rectal toxicity is reported to be associated with
an increased risk of late rectal sequela.36,50,51
The definition of rectal toxicity after radiotherapy is also a com-
plex issue. Various scales have been introduced and validated to
provide accurate report of the toxicity.18–20 However, ongoing con-
troversy on the best scale encouraged clinical trials which proposed
modifications.13,33 Accurate reporting of the toxicity is so impor-
tant because it is critical for the feedback of treatment development
which supports establishing the cause and effect. Dose-distribution
to the rectum is correlated with late rectal toxicity52–55 and devel-
opment of new techniques entailed new normal tissue constraints
to be developed. The constraints are not consistent in the literature
due to variations in collecting and reporting of toxicity. Last but
not least; rectal mucosal damage is not always directly correlated
with symptoms. Endoscopy is recommended for straight detection
of radiation injury in rectal mucosa. Even an endoscopic scaling sys-
tem; Vienna rectoscopy score (VRS), was presented for this purpose
in 200056 (Table 6). However, a scoring system must be applicable
in different centers and must have been used for a long time such
as the EORTC and RTOG score.
Type and severity of mucosal damage is reported to be related
to total dose and irradiated volume.21,22
5.2. Previous publications reporting on rectal radiation injury
after prostate IMRT
Zelefsky et al.57 reported late toxicity results of 561 patients
who had been treated with IMRT up to 81 Gy IMRT at the Memorial
Sloan–Kettering Cancer Centre. After 8 years of follow-up, the rate
of rectal bleeding was 1.6% and grade 3 rectal toxicity according to
the National Cancer Institute Common Toxicity Criteria (NCI-CTC)
was 0.1% with a fraction size of 1.8 Gy. Vora et al. reported acute
RTOG grade >2 toxicity in 49% (only 1% grade 3) in patients whose
rectal volume receiving >70 Gy was limited to 30%.58
The Gr 2 and 3 toxicities we reported in our patients were 16.7
% and 5.6 %, respectively, which was  not in accordance with the
above-mentioned results.
Although hypofractionation attempts are frequently reported,
in our patients we  used a conventional fractionation scheme of 200
cGy daily fractions. Pelvic lymph nodes were treated to 4600 cGy
followed by the first boost of 2400 cGy to a volume including the
seminal vesicles and prostate and the last boost of 600 cGy to the
prostate and proximal seminal vesicles.
In a recent study by Wortel et al., dose distributions in patients
with and without grade ≥2 acute proctitis were significantly
different for IG-IMRT and 3D-CRT. The authors demonstrated a sig-
nificant relationship between acute rectal toxicity and local dose
distributions. And they suggested that this finding could help to
develop consequent dose-effect models with improved dose con-
straints for IGRT or IMRT.59DVH, which is the basic tool for analyzing dose distribution and
treatment plan approval, is based on a CT planning-scan show-
ing only a snapshot of the patient anatomy.60 Besides, the spatial
components are also not represented in the DVH.61 Therefore,
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Table  6
Vienna Rectoscopy Score, Wachter et al.
VRS Mucosal Congestion Telangiectasia Ulceration Stricture Necrosis
0 Grade 1 (−) (−) (−) (−)
1  Grade 2 Grade 1 (−) (−) (−)


















































3  Any Grade 3 
4  Any Any 
5  Any Any 
lternative longitudinal definitions are proposed as done in TAME
tudy62 which defines a metric incorporating a number of aspects of
oxicity.63 Also, several definitions, such as integrated longitudinal
oxicity (ILT) for late rectal toxicity which incorporates the severity
nd duration of toxicity, were suggested in previous publications.64
nd it was recommended as a powerful measure while it is sensitive
o the differences in the time course of the different end-points.
ROC was another method which successfully derived con-
traints that indicating the incidence of toxicity. The advantage
f ROC analysis is the ability to explore all possible cut-points for
ach endpoint tested. The effects of confounding factors, such as
o-morbidities and individual patient radiation sensitivity,65 are
dded to the results. The same ROC method of analysis was sug-
ested to be applied to toxicity definitions which take into account
ongitudinal data. And two uncorrelated definitions of late rectal
oxicity to derive dose–volume constraints using ROC analysis were
emonstrated in the same study concluding that longitudinal def-
nition of toxicity adds value to the analysis of late toxicity data.63
Liu et al. validated a predictive model for late rectal bleeding
or patients treated with 74 Gy in 2 Gy/fraction. Rectal dose volume
istograms were extracted and fitted to a Lyman-Kutcher–Burman
TCP model. Multivariate logistic regression with dose-volume
arameters (V50, V60, V70, etc.) was found non-significant.66
hen we evaluated the convenience of our patients’ rectal dose
ata with QUANTEC dose suggestions, where RTOG dose limits
ere routinely taken into consideration in IMRT plans, we  were
nable to show any decrease in Gr 2–3 acute rectal toxicity with
ncreasing convenience to QUANTEC dose suggestions. Besides,
one of the dose-volume parameters suggested by QUANTEC was
ound significant in the Spearman’s correlation analysis in terms of
r 2–3 acute rectal toxicity.
Rectum Dmax was included in neither QUANTEC nor RTOG dose
uggestions. In concordance with this approach, no correlation was
ound between rectum Dmax and Gr 2–3 acute rectal toxicity. Some
revious studies reported a relation between absolute rectal vol-
me  exposed to a specific dose and acute rectal toxicity or rectal
leeding. Mirjolet et al. have shown that absolute rectal volume
xposed to 25 Gy–50 Gy may  predict any acute rectal toxicity.67
imilarly, Kotabe et al. also found that absolute rectal volume,
ather than relative rectal volume, exposed to 60 Gy is correlated
ith rectal bleeding in prostate IMRT treatment. And the authors
uggested the absolute rectal volume exposed to 60 Gy to be <5cc.68
n our study, TVrectum was found to be the only parameter signif-
cantly correlated with Gr 2–3 acute rectal toxicity.
There are several limitations of our study to be indicated. First is
 small patient group which obliged us to use nonparametric statis-
ical evaluation. Second is focusing the results on acute rectal injury
n a short follow up period. And the last one is the absence of any
bjective assessment, such as proctoscopy or pathologic examina-
ion.
. ConclusionsRectum dose parameters after IMRT treatment plans in prostate
ancer may  provide the tolerance doses suggested in RTOG guide-
ines where the same plan may  exceed QUANTEC dose limits. OurGrade 1 (−) (−)
Grade 2 Grade 1 (−)
Grade > 3 Grade > 2 (+)
results were not able to show any significant correlation between
increasing convenience with QUANTEC limits and lower rectal tox-
icity. Rectal volume was the only effective variable for prediction of
Gr 2–3 toxicity. Conclusively, new dosimetric definitions are war-
ranted to predict acute rectal toxicity more accurately in prostate
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